The global healthcare ecosystem is currently navigating a period of profound re-architecting, driven by the convergence of massive digital health data repositories and the unprecedented reasoning capabilities of Large Language Models (LLMs). This transition represents a departure from traditional, rule-based clinical decision support systems toward dynamic, generative architectures capable of interpreting the vast complexities of human physiology and clinical narrative. The

The Exit Factor: Why M&A is on the rise in HealthTech. By mid-2025 healthcare deal value had soared 87% to €31.8 billion, even as deal count slid 8% according to Nelson Advisors. In the UK, 168 healthtech exits landed by the end of 2024 against just 61 failures. M&A is no longer a side strategy; it’s the headline act and primary way buyers access innovation, capability, and competitive edge.

The global financial landscape in early 2026 has witnessed a profound structural shift, characterised by a transition from the speculative, capital-light growth models of the early 2020s toward a strategy centred on tangible infrastructure and physical resilience. At the heart of this transition is the emergence of the HALO effect, an investment and operational framework standing for Heavy Assets and Low Obsolescence. This paradigm prioritises companies that possess signific

On January 28, 2026, the trajectory of the global digital health market was irrevocably altered by Sword Health's announcement of its acquisition of Kaia Health. This transaction, valued at $285 Million, is not merely a consolidation of two competitors but a strategic unification of distinct technological philosophies, wearable sensor-based biofeedback and markerless computer vision, under a single, vertically integrated platform. This chapter dissects the financial mechanics

Nelson Advisors Thought Leadership article 'Corporate Divestitures in European Healthcare Technology: Trends in 2025' has been referenced in DC Advisory's 'European Healthcare M&A finds its pulse' report dated October 14, 2025.

The major stories in the world of European MedTech this week are dominated by regulatory activity under the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), a significant European Commission "Call for Evidence" for future reforms, and fresh funding for companies focused on connected and remote monitoring devices.

Nelson Advisors LLP, a UK-based firm, is explicitly and exclusively focused on providing mergers and acquisitions (M&A) advisory services within the healthcare technology sector across the United Kingdom, Europe, and North America. The firm’s core value proposition is rooted in a distinctive "practitioner-led" approach. This model is a direct function of the synergistic partnership between its two co-founders, whose professional backgrounds combine extensive corporate finance

This report provides a comprehensive analysis of Nelson Advisors LLP, a highly specialised London-based M&A and corporate advisory firm, and its strategic role in assisting healthcare technology (HealthTech) and MedTech companies with UK market entry. A central finding is the firm's use of a "Build, Buy, Partner, Sell" framework, which transcends traditional transactional advisory. This holistic model guides clients, particularly Western European and North American compan